- Home
- CARM vs BLRX Comparison
CARM vs BLRX Comparison
Compare CARM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- BLRX
- Stock Information
- Founded
- CARM 2016
- BLRX 2003
- Country
- CARM United States
- BLRX Israel
- Employees
- CARM N/A
- BLRX N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- BLRX Health Care
- Exchange
- CARM Nasdaq
- BLRX Nasdaq
- Market Cap
- CARM 35.5M
- BLRX 36.0M
- IPO Year
- CARM N/A
- BLRX 2011
- Fundamental
- Price
- CARM $0.47
- BLRX $0.20
- Analyst Decision
- CARM Hold
- BLRX Strong Buy
- Analyst Count
- CARM 5
- BLRX 2
- Target Price
- CARM $4.57
- BLRX $5.50
- AVG Volume (30 Days)
- CARM 329.1K
- BLRX 2.2M
- Earning Date
- CARM 11-07-2024
- BLRX 11-25-2024
- Dividend Yield
- CARM N/A
- BLRX N/A
- EPS Growth
- CARM N/A
- BLRX N/A
- EPS
- CARM N/A
- BLRX N/A
- Revenue
- CARM $20,268,000.00
- BLRX $21,991,000.00
- Revenue This Year
- CARM $46.34
- BLRX N/A
- Revenue Next Year
- CARM N/A
- BLRX N/A
- P/E Ratio
- CARM N/A
- BLRX N/A
- Revenue Growth
- CARM 41.13
- BLRX N/A
- 52 Week Low
- CARM $0.38
- BLRX $0.21
- 52 Week High
- CARM $3.16
- BLRX $1.70
- Technical
- Relative Strength Index (RSI)
- CARM 21.83
- BLRX 25.33
- Support Level
- CARM $0.38
- BLRX $0.23
- Resistance Level
- CARM $0.82
- BLRX $0.56
- Average True Range (ATR)
- CARM 0.06
- BLRX 0.03
- MACD
- CARM -0.03
- BLRX -0.00
- Stochastic Oscillator
- CARM 18.22
- BLRX 5.38
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.